Compounded GLP-1s and PCOS weight loss: what TikTok gets wrong

What did @jenniferokiegal actually say?

Honestly? Almost nothing medically substantive. The transcript captured is a repeated lyric or audio clip, "I'm gonna make some out of my money," which appears to be background audio rather than any clinical statement about GLP-1s, PCOS, or weight loss. The actual content was likely visual or caption-driven, pointing viewers to a referral link for compounded semaglutide or tirzepatide with a discount code.

The caption does the heavy lifting here: it references a "shortage" (implying brand-name GLP-1 scarcity), tags PCOS and weight loss, and drives traffic to what appears to be a telehealth platform offering compounded GLP-1 medications. The "compound" hashtag is the tell. This is an affiliate promotion, not a medical explainer.

Does the science back this up?

We can't fact-check audio that has no medical claims, so let's focus on what the post implies: that compounded GLP-1s are a reasonable option during shortage periods, particularly for people with PCOS. That part is worth unpacking, because the evidence is genuinely mixed.

GLP-1 receptor agonists like semaglutide have shown real promise for PCOS-related outcomes. A 2023 study by Jensterle et al. in the Journal of Clinical Endocrinology and Metabolism found semaglutide significantly reduced body weight and androgen levels in women with PCOS compared to placebo. Separate research from Cena et al. (2020, Nutrients) also linked GLP-1 agonist therapy to improved insulin sensitivity in PCOS patients. So the underlying therapeutic angle has support.

Compounded formulations are a different story. The FDA has repeatedly warned that compounded semaglutide is not the same as FDA-approved Ozempic or Wegovy. Purity, potency, and bioavailability are not guaranteed, and the agency removed semaglutide from its shortage list in 2024, which changes the legal landscape for compounders significantly.

What did they get wrong (or right)?

The post gets something directionally right: GLP-1 medications do have emerging evidence for PCOS, and cost and access are real barriers for patients. Those points aren't fabricated.

What's problematic is the framing. Referencing a "shortage" to justify compounded alternatives without clarifying that the FDA shortage designation has changed is misleading by omission. Viewers with PCOS who are already navigating confusing medical information may interpret this as straightforward advice to switch to compounded versions, without understanding that compounded drugs carry regulatory and quality risks that brand-name products don't.

The affiliate code structure also means the creator has a direct financial incentive in where viewers seek care. That doesn't automatically make the content wrong, but it's a conflict of interest that isn't disclosed beyond the vague caption structure. The FTC requires clear disclosure of material connections, and "click the link" with a promo code is a thin substitute for "I get paid if you sign up."

What should you actually know?

If you have PCOS and you're researching GLP-1 options, here's what actually matters. First, semaglutide and tirzepatide are not FDA-approved specifically for PCOS. They're approved for type 2 diabetes and chronic weight management. Any PCOS-specific use is off-label, which isn't inherently bad, but it means you need a clinician who knows the difference.

Second, compounded GLP-1s are not interchangeable with brand-name drugs. The FDA's position on this is unambiguous. If you're using a compounded version, you're accepting uncertainty about what's actually in the product. Some compounders are rigorous. Others aren't. You have no reliable way to tell from a TikTok referral link.

Third, cost is a legitimate concern. Brand-name GLP-1s can exceed $1,000 per month without insurance, and insurance coverage for weight management indications remains inconsistent. Compounded versions are cheaper. That trade-off is real, and dismissing it entirely isn't fair to patients. But the decision should happen with a clinician, not a promo code.